Intra-Cellular Therapies, Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
36
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 4 fees due Dec 16 to 23, 2026 · next Dec 16
- 2 fees due Jan 4 to 7, 2027 · next Jan 4
- 2 fees due Feb 15 to 18, 2027 · next Feb 15
- 3 fees due Mar 3 to 19, 2027 · next Mar 3
- 2 fees due Apr 3 to 27, 2027 · next Apr 3
- 5 fees due May 5 to 28, 2027 · next May 5
- 4 fees due Jun 1 to 19, 2027 · next Jun 1
- 2 fees due Jul 16 to 28, 2027 · next Jul 16
- 1 fee due Aug 9, 2027The maintenance fee for Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors (US 9,255,099) comes due Aug 9, 2027. Unpaid by Feb 9, 2028, it lapses early.
- 1 fee due Sep 24, 2027The maintenance fee for Organic compounds (US 10,597,394) comes due Sep 24, 2027. Unpaid by Mar 24, 2028, it lapses early.
- 2 fees due Oct 16, 2027
- 2 fees due Nov 14 to 17, 2027 · next Nov 14
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,470,548 | Diagnosis of depression In force · USPTO record | In force | USPTO record | |
| US 8,779,139 | Substituted 2,3,4,4A,5,9b-hexahydro-1H-pyrido[4,3-b]indole Derivatives Synthesis and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,315,504 | Preparation of 4-((6Br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-(7h)-yl)-1-(4-fluorophenyl)-1-butanone or a Pharmaceutically Acceptable Salt Thereof In force · High confidence | In force | High confidence | |
| US 9,751,883 | Preparation of Certain [((6br,10as)-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines and Pharmaceutically Acceptable Salts Thereof In force · High confidence | In force | High confidence | |
| US 10,221,176 | PREPARATION OF CERTAIN SUBSTITUTED [((6bR,10aS)-2,3,6b,7,8,9,10,10a-OCTAHYDRO-1H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALINES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF In force · High confidence | In force | High confidence | |
| US 10,464,938 | PHARMACEUTICAL COMPOSITIONS COMPRISING ((6bR,10aS)-1-(4-Fluorophenyl)-4-(3-Methyl-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF In force · High confidence | In force | High confidence | |
| US 10,597,395 | PREPARATION OF CERTAIN SUBSTITUTED 1-(4-Fluorophenyl)-4-(2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF In force · High confidence | In force | High confidence | |
| US 11,066,407 | PREPARATION OF CERTAIN SUBSTITUTED 1H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALINES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF In force · High confidence | In force | High confidence | |
| US 11,407,751 | HYDROCHLORIC ACID SALT OF (6bR,10aS)-3-Methyl-2,3,6b,7,8,9,10,10a-OCTAHYDRO-1H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALINE In force · High confidence | In force | High confidence | |
| US 12,139,490 | PROCESS FOR PREPARING 1-(4-Fluorophenyl)-4-((6bR,10aS)-3-Methyl-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE In force · High confidence | In force | High confidence |
Also on record, not counted in the 174: 2 patents in force now held by others · 3 lapsed for an unpaid fee · 4 ended at full term · 2 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
32 pending · 6 abandoned · 28 no status recorded